Skip to main content

Table 4 Univariate Cox regression analysis for HER2 and TOP2A adjusted for treatment

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

  Disease-free survival Overall survival
  HR 95% C.I. Wald's p HR 95% C.I. Wald's p
HER2 (CISH)       
   Non-amplified 1    1   
   Amplified 1.55 1.01-2.39 0.045 1.62 0.98-2.66 0.060
HER2 (mRNA)       
   Low 1    1   
   High 1.89 1.29-2.79 0.001 1.91 1.21-3.02 0.005
HER2 (IHC)       
   0-1+ 1    1   
   2+ 1.61 0.93-2.78 0.091 2.13 1.18-3.84 0.012
   3+ 1.75 1.10-2.79 0.019 1.78 1.02-3.08 0.041
HER2 status       
   Negative 1    1   
   Positive* 1.57 1.04-2.39 0.033 1.68 1.04-2.72 0.034
TOP2A (CISH)       
   Non-amplified 1    1   
   Amplified 0.35 0.11-1.10 0.072 0.34 0.08-1.38 0.131
TOP2A (mRNA)       
   Low 1    1   
   High 1.45 1.01-2.10 0.046 2.34 1.46-3.73 < 0.001
TopoIIa (IHC)       
   Negative 1    1   
   Positive 1.37 0.90-2.10 0.145 1.55 0.93-2.60 0.094
HER2/TOP2A CISH       
   All other 1    1   
   Both amplified 0.17 0.2-1.20 0.075 0.25 0.04-1.80 0.17
HER2/TOP2A mRNA       
   All other 1    1   
   Both high 2.15 1.37-3.38 0.001 2.51 1.51-4.18 < 0.001
HER2/TopoIIa IHC       
   All other 1    1   
   Both positive 1.92 1.14-3.25 0.015 1.89 1.04-3.44 0.038
  1. * IHC 3+ or CISH amplified.
  2. There was no interaction between examined markers with treatment regimens (p > 0.05 for all interaction tests).